Shenzhen Neptunus Bioengineering Co. Ltd. A | Ownership
Companies that own Shenzhen Neptunus Bioengineering Co. Ltd. A
ICBC Credit Suisse Asset Management Co., Ltd.
30,000,080
1.62%
11,000,080
0.24%
09/30/2017
Taikang Asset Management Co., Ltd.
19,346,327
1.04%
19,346,327
0.26%
09/30/2017
Zheshang Fund Management Co., Ltd.
16,840,304
0.91%
-35,839,554
5.31%
12/31/2017
China Investment Corp. (Investment Management)
10,394,250
0.56%
0
0.02%
09/30/2017
China Southern Asset Management Co., Ltd.
7,193,432
0.39%
-3,532,600
0.04%
12/31/2017
Rongtong Fund Management Co., Ltd.
6,777,498
0.37%
6,552,298
0.14%
12/31/2017
Shaanxi International Trust Co. Ltd. (Invt Mgmt)
6,721,729
0.36%
6,721,729
0.18%
09/30/2017
Penghua Fund Management Co., Ltd.
5,775,177
0.31%
2,658,500
0.03%
12/31/2017
Guotai Asset Management Co., Ltd.
4,252,895
0.23%
4,252,895
0.04%
12/31/2017
Lion Fund Management Co., Ltd.
3,261,050
0.18%
3,201,000
0.09%
12/31/2017
| Address |
24/F, Haiwang Yinhe Technology Bldg
Shenzhen Guangdong 518057
China
|
|
Employees
|
- |
| Website |
http://www.neptunus.com |
| Updated |
07/08/2019 |
| Shenzhen Neptunus Bioengineering Co., Ltd. engages in the research and development, production and distribution of pharmaceutical products. Its products include chemical pharmaceuticals, biological pharmaceuticals, antibiotics, narcotic drugs, biochemical drugs and other traditional Chinese medicines and herbs. The company was founded in 1989 and is headquartered in Shenzhen, China. |
